U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drugs@FDA

Drugs@FDA: FDA-Approved Drugs

Home | Previous Page

Abbreviated New Drug Application (ANDA): 078830
Company: PADAGIS US
Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
SCOPOLAMINE SCOPOLAMINE 1MG/72HR SYSTEM;TRANSDERMAL Prescription AB No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
01/30/2015 ORIG-1 Approval Label (PDF)
Letter (PDF)
Review (PDF)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/078830Orig1s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/078830Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/078830Orig1s000.pdf
Supplements
Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
10/27/2023 SUPPL-11 Labeling-Container/Carton Labels, Labeling-Medication Guide, Labeling-Package Insert

Label is not available on this site.

Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
Patient Package Insert
Note Url
01/30/2015 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/078830Orig1s000lbl.pdf

SCOPOLAMINE

SYSTEM;TRANSDERMAL; 1MG/72HR
TE Code = AB

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status RLD TE Code Application No. Company
SCOPOLAMINE SCOPOLAMINE 1MG/72HR SYSTEM;TRANSDERMAL Prescription No AB 208769 ACTAVIS LABS UT INC
SCOPOLAMINE SCOPOLAMINE 1MG/72HR SYSTEM;TRANSDERMAL Prescription No AB 203753 MYLAN TECHNOLOGIES
SCOPOLAMINE SCOPOLAMINE 1MG/72HR SYSTEM;TRANSDERMAL Prescription No AB 078830 PADAGIS US
SCOPOLAMINE SCOPOLAMINE 1MG/72HR SYSTEM;TRANSDERMAL Prescription No AB 212342 RICONPHARMA LLC
TRANSDERM SCOP SCOPOLAMINE 1MG/72HR SYSTEM;TRANSDERMAL Prescription Yes AB 017874 BAXTER HLTHCARE CORP
Back to Top